NCT00129753 2018-11-08
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT00081068 2013-01-08
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00226512 2011-04-08
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Hadassah Medical Organization
Phase 3 Withdrawn